Voyager Therapeutics(VYGR) - 2020 Q1 - Quarterly Report

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2020. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ______ to ______ Securities registered pursuant to Section 12(b) of the Act: Commission file number: 001-37625 Voyager Therapeutics, Inc. (Exact name o ...